Navigation Links
Oclaro Announces Second Quarter Fiscal Year 2013 Financial Results
Date:1/31/2013

g, general and administrative

23,09224,56614,425Amortization of intangible assets

2,4022,026723Restructuring, acquisition and related costs

(23,665)12,6363,219Flood-related expense

6412649,088(Gain) loss on sale of property and equipment

6(18)37Total operating expenses

28,22665,23944,516Operating loss

(6,727)(47,402)(33,641)Other income (expense):Interest income (expense), net

(649)(478)(245)Gain (loss) on foreign currency translation

(3,423)1961,298Other Income

--2,238Gain on bargain purchase

-39,460-Total other income (expense)

(4,072)39,1783,291Loss before income taxes

(10,799)(8,224)(30,350)Income tax provision

1,4241,183478Net loss

$
(12,223)$
(9,407)$
(30,828)Net loss per share: Basic

$
(0.14)$
(0.12)$
(0.61)Diluted

$
(0.14)$
(0.12)$
(0.61)Shares used in computing net loss per share: Basic

89,82780,21950,492Diluted

89,82780,21950,492Stock-based compensation included in the following:Cost of revenues 

$
524$
338$
388Research and development 

531376374Selling, general and administrative 

999886913Total

$
2,054$
,600$
,675 

  OCLARO, INC.RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES(unaudited, in thousands, except per share amounts)Three Months Ended December 29, 2012September 29, 2012December 31, 2011Reconciliation of GAAP net loss to non-GAAP net loss and adjusted EBITDA:GAAP net loss

$
(12,223)$
(9,407)$
(30,828)Stock-based compensation included in:Cost of revenues 

524338388Research and development 

531376374Selling, general and administrative 

999886913Amortization expense

2,4022,026723Restructuring, acquisition and related costs

(23,665)12,6363,219Flo
'/>"/>

SOURCE Oclaro, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Oclaro Announces Fourth Quarter and Fiscal Year 2012 Financial Results
2. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
3. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
4. Blue Belt Technologies Announces First U.S. Sale of NavioPFS Surgical System
5. IDEV Announces Results from Revascularization with Supera on Real World Patients (RESTORE) Study, Demonstrating Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions
6. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
7. Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
8. Kemwell Announces Successful Pre-NDA US FDA Inspection
9. Cell Therapeutics Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer
10. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
11. Vanish Announces Tattoo Removal Giveaway for Valentines Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... EDISON, N.J. , Aug. 4, 2015 /PRNewswire/ ... biopharmaceutical company focused on the development and commercialization ... Sapirstein , Chief Executive Officer, will present live ... DATE: Thursday, August 6, 2015 TIME: 12:15PM EDT ... will be a live, interactive online event where ...
(Date:8/4/2015)... Aug. 4, 2015 Among 1,000 U.S. consumers, ... only half of consumers surveyed are aware of prescription ... used use them, according to findings from a new ... service partnership focused on improving the health and well-being ... survey polled 1,000 men and women, ages 21 and ...
(Date:8/4/2015)... Calif., Aug. 4, 2015  Syneron Medical Ltd. (NASDAQ: ... financial results for the three month period ended June 30, ... Non-GAAP 1 Highlights: , Revenue ... currency. , North American product sales grew 45% year-over-year. ... constant currency, including 14% product growth in the EMEA region ...
Breaking Medicine Technology:ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3New Study Finds Consumers are Leaving Money at the Pharmacy 2New Study Finds Consumers are Leaving Money at the Pharmacy 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 2Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 4Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 5Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 6Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 7Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 8Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 9Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 10Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 11Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 12Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 13Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 14Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 15Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 16Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 17
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 2PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 3PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 4PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 5PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 6Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 2Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 3Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 4Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 5Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 6Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 7
(Date:8/4/2015)... ... 04, 2015 , ... Sin City Gallery is delighted to ... diverse group of exceptionally talented female artists. The exhibition premieres at the ... 25-27, 2015 in Downtown Las Vegas. Curated by gallery director Dr. Laura Henkel, ...
(Date:8/4/2015)... ... August 04, 2015 , ... MedicaSoft ... Office of the National Coordinator for Health Information Technology (ONC-HIT) 2014 Edition ... highest quality personal health record and patient portal solution to healthcare providers ...
(Date:8/4/2015)... ... August 04, 2015 , ... Driving skills may decline ... driving, says the August 2015 Harvard Health Letter. , "Age and health conditions ... an individual assessment of skills," says Lissa Kapust, a social worker at Harvard-affiliated ...
(Date:8/4/2015)... ... ... METTLER TOLEDO has announced an upcoming online symposium entitled ... and Merck. This free online seminar will be held on September 24, ... decisions with limited process understanding. Established methods have been developed to facilitate ...
(Date:8/4/2015)... ... August 04, 2015 , ... Half of consumers ... is board-certified is increasingly influential in their choice of practitioner, according to new ... Consumer Survey on Cosmetic Dermatologic Procedures reflects overall consumer views on cosmetic medical ...
Breaking Medicine News(10 mins):Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:METTLER TOLEDO Announces New Process Chemistry and Scale-up Online Seminar 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 4
... without gestational diabetes signals future heart risk, researcher says. , ... given to pregnant women may also show if they have ... new study has found. , This finding is important because ... for gestational diabetes to identify women who are at risk ...
... Aug. 24 /PRNewswire-Asia-FirstCall/ -- China Kangtai Cactus,Biotech, Inc. (OTC ... marketer of a variety of cactus-based products in,China, announced ... attend investor conference and meet with U.S. investors in ... roadshow details: , The company ...
... , WASHINGTON, Aug. 24 Secretary of ... (VA) is taking steps to assist Veterans seeking compensation for Post-Traumatic ... of war are being addressed vigorously and comprehensively by this administration ... century," said Secretary Shinseki. , , The VA ...
... , , AUBURN HILLS, ... (OTC Bulletin Board: ECOC), a leader in the discovery ... that it has signed a collaboration agreement with a ... for producing "fire standard compliant" (FSC) cigarettes. FSC cigarettes ...
... , ABBOTT PARK, Ill., Aug. 24 ... has received approval from Health Canada for the XIENCE V(R) Everolimus ... (CAD). XIENCE V is the only drug eluting stent to have ... the primary endpoints of two randomized, pivotal (phase III) clinical trials. ...
... , , CINCINNATI and ARDEE, Ireland, Aug. 24, ... Warner Chilcott plc (Nasdaq: WCRX ) today announced an agreement for ... cash payment of $3.1 billion. , , To view ... m nr/pg/39814/ , , (Logo: ...
Cached Medicine News:Health News:Glucose Challenge in Pregnancy Could Predict Heart Disease 2Health News:China Kangtai Cactus Biotech to Attend Rodman & Renshaw Conference and Meet with Investors in September 2Health News:China Kangtai Cactus Biotech to Attend Rodman & Renshaw Conference and Meet with Investors in September 3Health News:Secretary Shinseki Moves to Simplify PTSD Compensation Rules 2Health News:Ecology Coatings Signs Development Agreement with Major U.S. Tobacco Company 2Health News:Ecology Coatings Signs Development Agreement with Major U.S. Tobacco Company 3Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 2Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 3Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 4Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 5Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 2Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 3Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 4Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 5Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 6Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 7Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 8
...
... Tupos LV/A+, the single-lead principle has been applied ... The complete system, which consists of the Tupos ... the scope of surgery and the risk of ... and the ventricle via a single lead. The ...
... ICD cardiac resynchronization and ICD device offers ... The unit's RV only sensing provides no ... LV depolarizations, eliminating this cause of inappropriate ... LV separation for optimized hemodynamics. Proven PR ...
... The Medtronic InSync II Marquis incorporates ... ICD therapy. Cardiac resynchronization benefits include ... pacing outputs to unique patient needs. ... functions that help physicians manage heart ...
Medicine Products: